Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura

BMJ Case Reports

Volumn 2016, Issue , 2016, Pages

  Acedillo, Rey R ^a   Govind, Mayur ^a   Kashgary, Abdullah ^b   Clark, William F ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETRETIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; RITUXIMAB; USTEKINUMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABDOMINAL ABSCESS; ADULT; ARM WEAKNESS; ARTICLE; BALANCE IMPAIRMENT; BRAIN EDEMA; CASE REPORT; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; DECOMPRESSIVE CRANIECTOMY; EMPYEMA; FOLLOW UP; HEMATURIA; HEMIANOPIA; HUMAN; HUMAN CELL; LAPAROSCOPIC SURGERY; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; NEUROREHABILITATION; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; PSORIASIS; REMISSION; SEPSIS; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; WALKING DIFFICULTY; COMPLICATION; PATHOLOGY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

ADULT; BORTEZOMIB; BRAIN EDEMA; HUMANS; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 84974814364     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2016-215491     Document Type: Article

References (7)

1. Huang SH, Xenocostas A, Moist LM, et al. Ustekinumab associated thrombotic thrombocytopenic purpura. Transfus Apher Sci 2012;47:185-8.
2. Elliott MA, Heit JA, Pruthi RK, et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 2009;83:365-72.
3. Jhaveri KD, Scheuer A, Cohen J, et al. Treatment of refractory thrombotic thrombocytopenic purpura using multimodality therapy including splenectomy and cyclosporine. Transfus Apher Sci 2009;41:19-22.
4. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013;368:90-2.
5. George JN, López JA, Konkle BA. N-Acetylcysteine: an old drug, a new insight, a potentially effective treatment for thrombotic thrombocytopenic purpura. Transfusion 2014;54:1205-7.
6. Allan DS, Kovacs MJ, Clark WF. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001;86:844-50.
7. Clark WF, Rock G, Barth D, et al. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. Br J Haematol 2015;170:208-17.